Cargando…
Combining Crocin and Sorafenib Improves Their Tumor-Inhibiting Effects in a Rat Model of Diethylnitrosamine-Induced Cirrhotic-Hepatocellular Carcinoma
SIMPLE SUMMARY: Liver cancer represents one of the most lethal forms of cancer, with hepatocellular carcinoma (HCC) accounting for the majority of its incidences and deaths. Currently, sorafenib is the first-in-line option for treating advanced and unresectable HCC. It is a multi-kinase inhibitor th...
Autores principales: | Awad, Basma, Hamza, Alaaeldin Ahmed, Al-Maktoum, Amna, Al-Salam, Suhail, Amin, Amr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452334/ https://www.ncbi.nlm.nih.gov/pubmed/37627094 http://dx.doi.org/10.3390/cancers15164063 |
Ejemplares similares
-
Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights
por: Abdu, Suzan, et al.
Publicado: (2022) -
Steroidal Saponins: Naturally Occurring Compounds as Inhibitors of the Hallmarks of Cancer
por: Bouabdallah, Salwa, et al.
Publicado: (2023) -
Tumoral response and tumoral phenotypic changes in a rat model of diethylnitrosamine-induced hepatocellular carcinoma after salirasib and sorafenib administration
por: Ciccarelli, Olga, et al.
Publicado: (2018) -
Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
por: Jilkova, Zuzana Macek, et al.
Publicado: (2018) -
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model
por: Kurma, Keerthi, et al.
Publicado: (2022)